)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Neumora Therapeutics
Neumora Therapeutics (NMRA) investor relations material
Neumora Therapeutics Company presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company presentation summary14 Aug, 2026
Mission and leadership
Focused on developing next-generation, brain-penetrant therapies to improve outcomes and quality of life for patients with neurological and psychiatric disorders.
Led by experienced executives and board members with backgrounds in major pharmaceutical and biotech companies.
Strategic focus and market opportunity
Targeting large unmet needs in neuropsychiatric, neurodegenerative, and cardiometabolic diseases, which impact millions in the U.S.
Programs aim to provide novel mechanisms, improved tolerability, and oral treatment options for these conditions.
Pipeline and clinical development
Advancing three main franchises: NMRA-215 (obesity/cardiometabolic), NMRA-511 (Alzheimer’s agitation), and NMRA-898 (schizophrenia).
NMRA-215: Differentiated NLRP3 inhibitor showing class-leading weight loss, improved metabolic biomarkers, and potential for combination therapy with semaglutide.
NMRA-511: V1aR antagonist with strong efficacy and safety in Alzheimer’s agitation, especially in patients with elevated anxiety.
NMRA-898: M4 muscarinic receptor PAM for schizophrenia, optimized for CNS exposure and potency, with promising Phase 1 results.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Neumora Therapeutics
- Net loss narrowed, cash runway extends into Q3 2027, but going concern risk persists.NMRA
Q2 2026 - Advancing differentiated CNS therapies with strong efficacy and safety toward late-2026 milestones.NMRACorporate presentation
- Navacaprant's phase III COASTAL Program targets MDD and anhedonia, with pivotal data expected Q4.NMRAStatus Update
- Lead programs show strong efficacy and safety, with key clinical milestones expected in 2026.NMRAInvestor presentation
- Directors re-elected, auditor ratified, and annual executive pay votes approved.NMRAAGM 2026
- Navacaprant, NMRA-511, NMRA-215, and NMRA-898 advance with key data readouts and clinical milestones ahead.NMRARBC Capital Markets Global Healthcare Conference 2026
- Net loss narrowed to $53.5M as cash runway extends into Q3 2027 and pipeline advances.NMRAQ1 2026
- NMRA-215 showed up to 26% preclinical weight loss; multiple clinical catalysts expected in 2026.NMRAR&D Day 2025
- Pivotal Phase 3 MDD data expected year-end, with $341.3M cash runway into mid-2026.NMRAQ3 2024
Next Neumora Therapeutics earnings date
Q3 202620 Nov, 2026
Neumora Therapeutics
Next Neumora Therapeutics earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Neumora Therapeutics Inc., known as NMRA, is a clinical-stage biopharmaceutical company focused on the development of therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Founded in 2019 and formerly known as RBNC Therapeutics, Inc., Neumora aims to redefine neuroscience drug development by integrating data science with neuroscience to pioneer precision medicines for complex brain diseases. The company's pipeline includes various programs at different stages of clinical trials targeting diseases such as major depressive disorder, agitation associated with dementia due to Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Parkinson's disease, among others. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the Nasdaq.